Mesoblast Ltd (MESO) stock

MESONasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends June 30Also trades as MEOBF

Financials through fiscal 2026, year ended Jun 30, 2026Last filing: 20-F on Aug 27, 2026Score 6/30

$13.27+0.17 (+1.30%)

Close on Nov 13, 2026Market cap $1.72BP/E –Yield –

Mesoblast EPS

Diluted earnings per share is net income divided by the share count including options and convertible securities.

Mesoblast's EPS for the twelve months ending Jun 30, 2023 was -$0.11. For fiscal 2026 it was -$0.04. The highest annual figure on record is -$0.01 in fiscal 2016.

Annual eps

Period	Period end	Value	Change
FY2026	Jun 30, 2026	-$0.04	–
FY2025	Jun 30, 2025	-$0.08	–
FY2024	Jun 30, 2024	-$0.09	–
FY2023	Jun 30, 2023	-$0.11	–
FY2022	Jun 30, 2022	-$0.13	–
FY2021	Jun 30, 2021	-$0.16	–
FY2020	Jun 30, 2020	-$0.15	–
FY2019	Jun 30, 2019	-$0.18	–
FY2018	Jun 30, 2018	-$0.08	–
FY2017	Jun 30, 2017	-$0.19	–
FY2016	Jun 30, 2016	-$0.01	–

Quarterly eps

Change is against the same quarter a year earlier.

Periods

Period	Period end	Value	Change
Q4 FY2023CQ2 2023	Jun 30, 2023	-$0.02	–
Q3 FY2023CQ1 2023	Mar 31, 2023	-$0.03	–
Q2 FY2023CQ4 2022	Dec 31, 2022	-$0.03	–
Q1 FY2023CQ3 2022	Sep 30, 2022	-$0.02	–
Q4 FY2022CQ2 2022	Jun 30, 2022	-$0.03	–
Q3 FY2022CQ1 2022	Mar 31, 2022	-$0.03	–
Q2 FY2022CQ4 2021	Dec 31, 2021	-$0.04	–
Q1 FY2022CQ3 2021	Sep 30, 2021	-$0.03	–
Q3 FY2021CQ1 2021	Mar 31, 2021	-$0.04	–
Q2 FY2021CQ4 2020	Dec 31, 2020	-$4.38	–
Q1 FY2021CQ3 2020	Sep 30, 2020	-$4.21	–
Q3 FY2020CQ1 2020	Mar 31, 2020	-$2.84	–
Q2 FY2020CQ4 2019	Dec 31, 2019	-$4.60	–
Q1 FY2020CQ3 2019	Sep 30, 2019	-$1.10	–
Q4 FY2019CQ2 2019	Jun 30, 2019	-$0.04	–
Q3 FY2019CQ1 2019	Mar 31, 2019	-$0.05	–
Q2 FY2019CQ4 2018	Dec 31, 2018	-$0.05	-271.8%
Q1 FY2019CQ3 2018	Sep 30, 2018	-$0.04	–
Q4 FY2018CQ2 2018	Jun 30, 2018	-$0.04	–
Q3 FY2018CQ1 2018	Mar 31, 2018	-$0.04	–
Q2 FY2018CQ4 2017	Dec 31, 2017	$0.03	–